TNF and rheumatoid arthritis: The ‘Dose REduction Strategy of Subcutaneous TNF inhibitors’ (DRESS) study was the first randomized controlled study in RA investigating disease activity–guided dose optimization of adalimumab or etanercept compared with continuation over a period of 18 months [5].